Details

Autor(en) / Beteiligte

• Mayén, Ana-Lucia
• Sabra, Mirna
• Aglago, Elom K
• Perlemuter, Gabriel
• Voican, Cosmin
• Ramos, Ines
• Debras, Charlotte
• Blanco, Jessica
• Viallon, Vivian
• Ferrari, Pietro
• Olsen, Anja
• Tjønneland, Anne
• Langmann, Fie
• Dahm, Christina C
• Rothwell, Joseph
• Laouali, Nasser
• Marques, Chloé
• Schulze, Matthias B
• Katzke, Verena
• Kaaks, Rudolf
• Palli, Domenico
• Macciotta, Alessandra
• Panico, Salvatore
• Tumino, Rosario
• Agnoli, Claudia
• Farràs, Marta
• Molina-Montes, Esther
• Amiano, Pilar
• Chirlaque, María-Dolores
• Castilla, Jesús
• Werner, Mårten
• Bodén, Stina
• Heath, Alicia K
• Tsilidis, Kostas
• Aune, Dagfinn
• Weiderpass, Elisabete
• Freisling, Heinz
• Gunter, Marc J
• Jenab, Mazda

Titel

Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study

Ist Teil von

• BMC medicine, 2024-06, Vol.22 (1), p.221-221, Article 221

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2024

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality. We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed. Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI ≥ 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality. Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.